Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.5952W HIGH $35.87
Volume
150.00 K
Value Traded
20.21 M
Short % Float
12.33%
Days to Cover
2.8
+5.12%Week
+10.21%1 Month
+0.22%3 Month
-13.79%6 Month
-74.02%5 Year
+140.52%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.16 B
EPS (TTM)
0.08
P/E Ratio
300.26
Ent. Value
975.08 M
Total Shares
50.14 M
Float Shares
30.32 M
Insiders
39.53%
Institutions
73.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
STAA Catalyst Timeline
Dated clinical, regulatory and corporate events for STAAR Surgical Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for STAAR Surgical Company
6Total events
2Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T2Management Change
Subscribe to view catalyst details
Event history 4
●Quarterly UpdateCorporate
STAAR Surgical to release Q2 2026 financial results and shareholder letter
●Management ChangeCorporate
Deborah Andrews appointed Executive Vice President and continues as Chief Financial Officer
●Management ChangeCorporate
New Chief Executive Officer of STAAR writing first shareholder letter
▲Product LaunchEVOPost-Market
Successful launch of EVO+ in China in the first quarter
myopia / vision correctionsource ↗
Past FDA Catalysts and PDUFA Decisions
How STAA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
STAAR Surgical Company is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every STAA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Foust WarrenOfficer (President and CEO) | Option | 7,331 93,887 held | $0.00 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STAA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % | 374.00 K | 20.00 K | -20% ( -5.00 K) |
STAA Institutional Ownership Trends
STAA Short Interest
Shares sold short, counted twice a month.
12.33%
Short % of Float
of tradable shares sold short
3.7M
Shares Sold Short
-19.3% vs prior count
2.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STAA ranks across every disease it competes in
Competitive Position is a premium feature
See how STAA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTAA News
STAASTAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026
STAAR Surgical Company will release its financial results for Q3 2026 on November 4, 2026. The company, known for its EVO family of Implantable Collamer Lenses, will also host a call and webcast at 5:30 p.m. ET to discuss the results. This event follows the close of the market on the same day.
Read more →STAASTAAR Surgical Names Andrew Pilon as Vice President of Business Development
STAAR Surgical has appointed Andrew Pilon, O.D., as the new Vice President of Business Development. Dr. Pilon will report directly to the company's President and CEO, Warren Foust. His role will involve working closely with the senior leadership team to explore and capitalize on business opportunities.
Read more →STAAVerbraucherumfrage von STAAR Surgical: 71 Prozent der Deutschen möchten auf Sehhilfen verzichten, kennen aber ihre Alternativen nicht
STAAR Surgical released findings from a global consumer survey on vision correction. In Germany, 1,000 adults were surveyed, revealing that 71% prefer to avoid vision aids but lack knowledge about alternatives. This indicates a potential market for educating consumers on refractive surgery options.
Read more →STAA▲ +7.5%on this news· ran to +19% by day 3shared move
STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
STAAR Surgical Company has announced a $50 million share repurchase program approved by its Board of Directors. This initiative allows the company to buy back its outstanding common stock, potentially increasing shareholder value. The decision reflects the board's confidence in the company's financial health and future prospects.
Read more →STAASTAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
STAAR Surgical has published a significant report titled 'The Future of Refractive Surgery,' which reveals a global trend towards lens-based vision correction. This report indicates a robust demand for implantable lens correction, supported by favorable clinical factors. The findings suggest a structural shift in the market, emphasizing the growing preference for EVO ICLs.
Read more →STAASTAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
STAAR Surgical has appointed David Bailey as Chief Commercial Officer, who will be part of the executive committee and report to the CEO. Bailey's extensive knowledge of STAAR is anticipated to positively influence the company's commercial strategies and growth trajectory.
Read more →STAASTAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer
STAAR Surgical has appointed Ben Park, Ph.D., as Chief Technology Officer. This strategic move aims to transition the company from a single-product focus to a multi-product platform. Dr. Park will be part of the Executive Committee and report directly to the CEO, Warren Foust.
Read more →STAASTAAR Surgical Reports Second Quarter 2026 Results
STAAR Surgical Company reported a significant increase in net sales for the second quarter of 2026, reaching $93.5 million, which represents a 111% increase year-over-year. Notably, sales in China exceeded $52 million, marking a growth of over 100%. Additionally, the company's performance in the APAC region showed a remarkable increase of 189% year-over-year.
Read more →STAA▼ -5.2%on this news
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
STAAR Surgical has appointed Warren Foust as its new President and CEO, effective August 4, 2026. Foust, who joined the company in April 2023, will also serve on the Board of Directors. This leadership change follows a thorough global search by the Board.
Read more →STAA▼ -5.2%on this newsshared move
STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026
STAAR Surgical Company has announced the release of its financial results for the second quarter of 2026, scheduled for August 12, 2026. The results will be accompanied by a shareholder letter and followed by an earnings call and webcast at 5:30 p.m. ET. This event aims to discuss the company's financial performance.
Read more →STAA▼ -8.8%on this news
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026
STAAR Surgical Company has reported strong preliminary net sales for the second quarter of 2026, exceeding expectations. This announcement comes ahead of their quarterly earnings report scheduled for August 12, 2026. The company maintains its position as a leader in the phakic IOLs market with its EVO family of lenses.
Read more →STAASTAAR Surgical Announces Participation in Upcoming Investor Conferences
STAAR Surgical has announced its participation in several upcoming investor conferences. The details regarding the specific conferences and the topics to be discussed were not provided in the article. This participation may present opportunities for the company to engage with investors and stakeholders.
Read more →STAASTAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
STAAR Surgical has reported its financial results for the first quarter of 2026 and issued a letter to shareholders. The report includes key financial metrics and insights into the company's performance during this period. Further details on the company's strategic direction and future outlook may be provided in the shareholder letter.
Read more →STAASTAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
STAAR Surgical has announced it will host its first quarter 2026 earnings results call and webcast on May 13, 2026. This event will provide stakeholders with insights into the company's financial performance for the quarter. Further details regarding the call will likely be shared closer to the date.
Read more →STAASTAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
STAAR Surgical has announced its preliminary net sales for the first quarter of 2026. The announcement highlights the company's financial performance but lacks detailed insights into specific sales figures or growth metrics. The news is presented without any significant positive or negative implications.
Read more →STAASTAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results Confident in China Progress and Future Roadmap
STAAR Surgical Company announced its financial results for the fourth quarter and fiscal year 2025, highlighting a net sales increase of 18.1% year-over-year driven largely by the performance in China. The company reported a net loss of $(18.3) million in Q4, though this was an improvement from the previous year's loss. Improved gross margins and reduced operational losses were noted as positive trends. Looking ahead, STAAR's leadership expressed optimism regarding growth prospects in China and the launch of their new EVO+ ICL product.
Read more →STAASTAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
STAAR Surgical has announced the sale of over 4 million Implantable Collamer Lenses (ICLs) globally, highlighting a significant shift from laser-based vision correction to lens-based solutions. This milestone reflects the increasing preference among patients and surgeons for minimally invasive procedures that preserve corneal integrity. The company's EVO ICL platform continues to gain traction, supported by expanded regulatory indications and positive clinical outcomes.
Read more →STAA▲ +8.5%on this newsshared move
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026
STAAR Surgical Company will announce its financial results for the fourth quarter and fiscal year 2025 on March 3, 2026. An earnings call and webcast will follow at 5:30 p.m. ET to discuss these results and the company's progress. The event underscores STAAR's commitment to transparency with investors.
Read more →STAA▲ +8.4%on this news
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
The FDA has expanded the age indication for EVO ICL, allowing its use for patients aged 21 to 60. This change increases the potential market by nearly 8 million patients and comes alongside positive long-term safety data from clinical trials. The refractive vision correction market is shifting away from laser procedures, with EVO ICL gaining popularity among patients with high myopia.
Read more →STAASTAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
STAAR Surgical has appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 1, 2026. The Board of Directors expressed confidence in their leadership during this transitional period. A Search Committee has been formed to find a permanent CEO, engaging both internal and external candidates. Foust and Andrews bring extensive experience to their roles.
Read more →About STAAR Surgical Company
Headquarters1911 WALKER AVE, MONROVIA, CA, 91016
BIOPHARMAWATCH ELITE PLUS
Trade the next STAA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime